Department of Medicine, Division of Endocrinology and Metabolism
Letter to the Editor
Cardiovascular Diseases | Endocrine System Diseases | Endocrinology, Diabetes, and Metabolism | Nutritional and Metabolic Diseases
SGLT2 inhibitor (SGLT2i) class of medications are known to cause to euglycemic diabetic ketoacidosis (euDKA) as reported in the article by Lin et al. in your esteemed publication about this entity being reported for the first time in Taiwanese population.We wish to share the findings from our center to further expand the spectrum of findings associated with SGLT2i therapy.
Cardiovascular, Euglycemic-diabetic ketoacidosis, Ketonemia, SGLT2
Rights and Permissions
Copyright 2019, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
DOI of Published Version
J Formos Med Assoc. 2019 May 14. pii: S0929-6646(19)30390-0. doi: 10.1016/j.jfma.2019.04.021. [Epub ahead of print] Link to article on publisher's site
Journal of the Formosan Medical Association = Taiwan yi zhi
Thapa, Simant Singh; Lal, Amos; Omer, Abdulkadir; and Trivedi, Nitin, "Elevated beta-hydroxybutyric acid with no ketoacidosis in type 2 diabetic patients using sodium-glucose cotransporter-2 inhibitors" (2019). Open Access Articles. 3855.
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.